OFFICE OF PROFESSIONAL LICENSURE AND CERTIFICATION
STATE OF NEW HAMPSHIRE
DIVISION OF HEALTH PROFESSIONS
Board of Pharmacy
Prescription Drug Monitoring Program
121 South Fruit Street
Concord, N.H. 03301-2412
Telephone 603-271-2350 · Fax 603-271-2856

PETER DANLES
Executive Director

SHERI WALSH
Health Profession Director

MICHAEL BULLEK
Administror/Chief of Compliance

MICHELLE RICCO JONAS
Program Manager


PDMP UPDATE

Health and Human Services Oversight Committee
November 9, 2018

- Migrated the PDMP over to a new vendor – APPRISS Health in July 2017.
- Board of Pharmacy/NH Prescription Drug Monitoring Program received a program audit. The Board provided a response plan to the audit in January 2018 and has provided monthly updates.
- PDMP staff worked with consultants from PDMP Training and Technical Assistance to conduct a 2-day strategic planning session in June 2018, with over 35 stakeholders in attendance.
- PDMP staff worked with Advisory Council to draft threshold criteria, which the Board approved in July 2018. These criteria included multiple prescriber/pharmacy, concurrent opioid/benzodiazepine prescriptions and morphine milligram equivalency (MME) over 100.
- PDMP hired a full time analyst in August 2018.
- PDMP collaborated with DHHS to secure funding for provide enhancements to the PDMP system that will include, Clinical Reports, Prescriber Report Cards, and Mandate Monitoring System. Additionally, funds to hire 2 part-time staff to conduct an audit of the PDMP data.
- Attained and working with practitioner DEA list to compare with PDMP registration list to ensure that all that are required to register are registered with the NH PDMP.
- Attained and working with waivered provider list from SAMHSA to track how many practitioners who can prescribe for medication assisted therapy are actually practicing in NH and where they are practicing – analysis of this data to be provided to appropriate regulatory boards and de-identified data to state partners.
- PDMP staff submitted a draft strategic plan for initial review to the Board of Pharmacy in October 2018 – awaiting vote from the Board and direction on next steps.

Attached is a sampling of the data we are working on for the PDMP Annual Report.


Count of Prescriptions by DEA Drug Schedule by SFY Quarter



	2016 Q1	2016 Q2	2016 Q3	2016 Q4	2017 Q1	2017 Q2	2017 Q3	2017 Q4	2018 Q1	2018 Q2	2018 Q3	2018 Q4
DEA Sched 2	262,341	260,979	249,396	244,302	240,228	237,798	218,858	211,901	203,485	198,318	187,252	182,495
DEA Sched 3	8,276	8,042	7,749	7,326	6,896	6,879	6,187	6,078	5,809	5,597	5,407	5,176
DEA Sched 4	220,543	220,943	213,797	212,047	213,189	208,140	200,258	198,802	196,604	192,067	187,815	183,303

Data Source: NH Prescription Drug Monitoring Program

Total Quantity of Dispensed Units (includes Tablets, Capsules, but no liquids)



	2016 Q1	2016 Q2	2016 Q3	2016 Q4	2017 Q1	2017 Q2	2017 Q3	2017 Q4	2018 Q1	2018 Q2	2018 Q3	2018 Q4
DEA Drug Sched 2	14,217,760	14,128,923	13,310,410	13,010,475	12,796,124	12,626,987	11,854,173	11,646,598	11,253,077	10,904,321	10,243,967	9,991,633
DEA Drug Sched 3	320,243	310,094	290,101	279,278	267,529	262,136	236,057	235,746	227,027	219,356	207,430	197,764
DEA Drug Sched 4	12,094,636	12,122,924	11,648,612	11,538,786	11,568,880	11,269,377	10,816,387	10,797,179	10,574,589	10,207,937	9,887,685	9,614,359

Data Source: NH Prescription Drug Monitoring Program

Registered User Increase

as of November 5, 2018

Registered Users by User Role			
User Role	**User Count as of July 1, 2018**	**User Count as of November 5, 2018**	**Increase in User Count**
Physician (MD, DO)	4,464	4,612	148
Pharmacist	3,012	3,095	83
Nurse Practitioner / Clinical Nurse Specialist	2,025	2,134	109
Prescriber Delegate - Unlicensed	1,846	2,008	162
Prescriber Delegate - Licensed	1,298	1,402	104
Dentist	1,053	1,087	34
Physician Assistant	793	839	46
Veterinarian	327	336	9
Medical Resident with Prescriptive Authority	247	299	52
Optometrist	232	237	5
Podiatrist (DPM)	93	93	0
Naturopathic Physician	32	33	1
Pharmacist's Delegate - Licensed	29	33	4
Pharmacist's Delegate - Unlicensed	10	17	7
VA Prescriber	2	4	2
Medical Examiner - Delegate	1	2	1
Medical Examiner/Coroner	0	1	1
VA Dispenser	0	1	1
Total Users	**15,464**	**16,233**	**769**

Data Source: NH Prescription Drug Monitoring Program

Utilization Since July 2017 Transition to New Software

User Role-Requests	2017 (6 months)	2018 (10 months)	Total July 25, 2017 thru Nov 5, 2018
Physician (MD, DO)	42,056	72,505	114,561
Pharmacist	85,029	201,438	286,467
Nurse Practitioner / Clinical Nurse Specialist	28,051	59,371	87,422
Prescriber Delegate - Unlicensed	94,236	236,306	330,542
Prescriber Delegate - Licensed	55,418	119,563	174,981
Dentist	9,370	21,008	30,378
Physician Assistant	16,443	25,591	42,034
Veterinarian	150	133	283
Medical Resident with Prescriptive Authority	1,817	4,084	5,901
Optometrist	0	1	1
Podiatrist (DPM)	643	1,421	2,064
Naturopathic Physician	7	49	56
Pharmacist's Delegate - Licensed	1,294	3,200	4,494
Pharmacist's Delegate - Unlicensed	44	1,212	1,256
VA Prescriber	0	9	9
Medical Examiner - Delegate	0	143	143
Medical Examiner/Coroner	0	10	10
VA Dispenser	12	94	106
Total	**334,570**	**746,138**	**1,080,708**

Data Source: NH Prescription Drug Monitoring Program

Methodology and Notes

The source data is Appriss AWARE PMP software, queried between October 15, 2018 and November 5, 2018.

Slides 1, 2 and 3 are slides with prescription counts. They each use the same methodology for data selection:

- State Fiscal Years 2016 thru 2018, which are July 1, 2015 thru June 30, 2018, displayed as quarters.
- The DEA Schedules included are Schedule 2, 3 and 4 (defined further on), which constitute Controlled Substances.
- Units are "Each", e.g. tablets, capsules, patches, etc. Excluded are liquids, powders (used for compounding), syrups, etc.
- Excluded are the generic drugs Buprenorphine, Buprenorphine HCL and Buprenorphine/Naloxone as those are currently used for recovery.
- Excluded are any "Unspecified" items. "Unspecified" constitute 4 one-hundredths of one percent of prescription counts (0.04% when choosing to filter by DEA Schedule "Unspecified"). So we're counting 99.96% of prescriptions.

Slide 4 shows Registered Users and the increase occurring from July 1, 2018 through November 5, 2018.

- Registered Users are users which have access to the PDMP.

Slide 5 shows Utilization by Registered Users.

- Utilization is the number of times a registered user has accessed the PDMP to request information on a specific patient.

Slide 6 - Opioid Prescriptions Only- uses the same methodology as slides 1, 2 and 3, but ONLY INCLUDES Opioids in AHFS Drug categories. Included categories are Opiates, Opiate Antagonists and Opiate Partial Agonists.

DEA Drug Schedules are defined as:
Schedule 2- drugs with a high potential for abuse, with use potentially leading to severe psychological or physical dependence. These drugs are also considered dangerous. Some examples of Schedule 2 drugs are: Combination products with less than 15 milligrams of hydrocodone per dosage unit (Vicodin), cocaine, methamphetamine, methadone, hydromorphone (Dilaudid), meperidine (Demerol), oxycodone (OxyContin), fentanyl, Dexedrine, Adderall, and Ritalin.
Schedule 3 – drugs with a moderate to low potential for physical and psychological dependence. Schedule 3 drugs abuse potential is less than Schedule I and Schedule II drugs but more than Schedule 4. Some examples of Schedule 3 drugs are: Products containing less than 90 milligrams of codeine per dosage unit (Tylenol with codeine), ketamine, anabolic steroids, testosterone.
Schedule 4 - drugs with a low potential for abuse and low risk of dependence. Some examples of Schedule 4 drugs are: Xanax, Soma, Darvon, Darvocet, Valium, Ativan, Talwin, Ambien, Tramadol.